CD19 and acute lymphoblastic leukemia: Two bispecific antibodies have already been approved, Catumaxomab and Blinatumomab, targeting EpCAM and CD3 and CD19 and CD3 in malignant ascites and acute lymphoblastic leukemia, respectively (Suurs et al., 2019).